|
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer Clinical research trials and Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer. Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer clinical trial. Test subjects typically obtain the finest healthcare available for their Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer  Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer
For Condition: stage 3 pancreatic cancer,stage 4A pancreatic cancer,adenocarcinoma of the pancreas
Status: No longer recruiting
Sponsor(s): North Central Cancer Treatment Group , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus radiation therapy in treating patients who have locally advanced pancreatic cancer.
Details: OBJECTIVES: - Determine the efficacy of gemcitabine, cisplatin, and radiotherapy, in terms of 1-year survival, in patients with locally advanced pancreatic cancer. - Determine the toxicity of this regimen in these patients. - Determine the quality of life of patients treated with this regimen. OUTLINE: This is a multicenter study. Patients undergo radiotherapy once daily five days a week for 5.5 weeks. Patients receive gemcitabine IV over 30 minutes followed by cisplatin IV over 1 hour twice a week for the first 3 weeks of radiotherapy. Beginning 4 weeks after the completion of radiotherapy, patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for a total of 3 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline, at completion of radiotherapy, at completion of chemotherapy, and 3 months after completion of therapy. Patients are followed every 3 months for 2 years and then every 6 months for 1 year. PROJECTED ACCRUAL: A total of 20-47 patients will be accrued for this study within 12-28 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed unresectable adenocarcinoma of the pancreas - No cystadenocarcinoma of the pancreas or pancreatic tumors of neuroendocrine origin - Prior subtotal resection or gross residual disease - No microscopic residual disease only - No metastatic disease outside of planned study radiotherapy field PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - ECOG 0-1 Life expectancy: - Not specified Hematopoietic: - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic: - Bilirubin no greater than 2 times upper limit of normal (ULN) - AST no greater than 3 times ULN Renal: - Creatinine no greater than 1.5 times ULN Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - Able to maintain adequate oral nutrition - No significant infection - No other medical condition that would preclude study - No other malignancy within the past 5 years except non-melanoma skin cancer - No significant nausea or vomiting PRIOR CONCURRENT THERAPY: Biologic therapy: - No prior or concurrent biologic therapy Chemotherapy: - No prior chemotherapy - No other concurrent chemotherapy Endocrine therapy: - Not specified Radiotherapy: - See Disease Characteristics - No prior radiotherapy that would overlap planned study radiotherapy fields Surgery: - See Disease Characteristics - At least 21 days since prior laparotomy
Total Enrollment:
Location and Contact Information:
Overall Study Official:
MichaelHaddock, Study Chair, Mayo Clinic Cancer Center
Methodist Medical Center of Illinois
Peoria, Illinois, 61636
United States
CCOP - Missouri Valley Cancer Consortium
Omaha, Nebraska, 68106
United States
Rapid City Regional Hospital
Rapid City, South Dakota, 57709
United States
CCOP - Carle Cancer Center
Urbana, Illinois, 61801
United States
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905-0001
United States
MBCCOP - Howard University Cancer Center
Washington D.C., District of Columbia, 20060
United States
CCOP - Scottsdale Oncology Program
Scottsdale, Arizona, 85259-5404
United States
CCOP - Ochsner
New Orleans, Louisiana, 70121
United States
Siouxland Hematology-Oncology
Sioux City, Iowa, 51101-1733
United States
CCOP - Metro-Minnesota
St. Louis Park, Minnesota, 55416
United States
CCOP - Sioux Community Cancer Consortium
Sioux Falls, South Dakota, 57104
United States
CCOP - Cedar Rapids Oncology Project
Cedar Rapids, Iowa, 52403-1206
United States
CCOP - Toledo Community Hospital
Toledo, Ohio, 43623-3456
United States
CCOP - Duluth
Duluth, Minnesota, 55805
United States
Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1
Canada
CCOP - St. Vincent Hospital Cancer Center, Green Bay
Green Bay, Wisconsin, 54301
United States
CCOP - Illinois Oncology Research Association
Peoria, Illinois, 61602
United States
Altru Cancer Center
Grand Forks, North Dakota, 58201
United States
CCOP - Geisinger Clinic and Medical Center
Danville, Pennsylvania, 17822-2001
United States
CCOP - Merit Care Hospital
Fargo, North Dakota, 58122
United States
CCOP - Michigan Cancer Research Consortium
Ann Arbor, Michigan, 48106
United States
CCOP - Wichita
Wichita, Kansas, 67214-3882
United States
Medcenter One Health System
Bismark, North Dakota, 58501-5505
United States
Allegheny General Hospital
Pittsburgh, Pennsylvania, 15212-4772
United States
CentraCare Health Plaza
St. Cloud, Minnesota, 56303
United States
CCOP - Iowa Oncology Research Association
Des Moines, Iowa, 50309-1016
United States
Additional Information:
Study ID Numbers: CDR0000069026; NCCTG-N9942
Study Start Date:
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00026403
Other Adenocarcinoma Of The Pancreas Studies:
1. Flavopiridol Plus Radiation Therapy Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer
2. Electroporation Therapy With Bleomycin in Treating Patients With Pancreatic Cancer
3. Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors
4. Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer
5. Phase I Study of Vaccination With MUC-1 Antigen and Immunologic Adjuvant SB AS-2 in Patients With Resected or Locally Advanced Unresectable Pancreatic Cancer
Related Studies:
Other adenocarcinoma of the pancreas Clinical Trials
Other Minnesota Clinical Trials
Other St. Louis Park Clinical Trials
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer
|
|
|
|
|
|
|
|
